Treatment of autoimmune and extra-hepatic manifestations of HCV infection.
Hepatitis C virus (HCV) infects mononuclear cells and may, like other viruses, cause immunological disorders. Immunological abnormalities observed in HCV infections are usually nonspecific (e.g. cryoglobulinemia, immune complex deposits, autoantibodies). There is a clear association between cryoglobulinemia and hepatitis C and cryoglobulinemia related symptoms are usually improved by treatment with interferon alpha, although patients usually relapse after treatment end. The relationships between hepatitis C and other immunological abnormalities are unclear. The association between chronic hepatitis C and anti-smooth muscle or anti-nuclear antibodies does not appear to be significantly different from that in other hepatic disorders, particularly hepatitis B. Conversely, patients with hepatitis C have significantly more often anti-liver kidney microsomal (LKM1) antibodies than patients with other causes of liver diseases. When clinical, histological and biological findings are indicative of HCV infection with chronic hepatitis, interferon alpha or combination therapy with ribavirin are treatments options. Conversely, when clinical context and results of laboratory tests are in favor of an autoimmune disorder or of overlap-syndromes (i.e. both autoimmune and viral hepatitis), interferon should not be given in first intention, since revelation or exacerbation of autoimmune hepatitis have been reported under interferon. An important prevalence of anti-HCV antibodies has also been reported in patients with sialadenitis, lichen planus and thyroiditis. It has been clearly demonstrated that interferon may induce or worsen such immunological diseases, but there are very few studies showing improvement of these manifestations under interferon. In conclusion, interferon may be appropriate in patients with HCV infection and extrahepatic manifestations linked to immune complex deposition, whereas, in other cases, careful assessment of patients with autoimmune processes is necessary before choosing any treatment strategy.
Lunel
F
F
Laboratoire de Bactério-Virologie, CHU Angers.
Cacoub
P
P
D000998:Antiviral Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000628:therapy* / Q000821:virology; D003449:Cryoglobulinemia / Q000628:therapy / Q000821:virology; D016174:Hepacivirus / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D007105:Immune Complex Diseases / Q000628:therapy / Q000821:virology; D016898:Interferon-alpha / Q000627:therapeutic use; D007668:Kidney / Q000276:immunology / Q000648:ultrastructure; D008010:Lichen Planus / Q000276:immunology / Q000821:virology; D008861:Microsomes / Q000276:immunology; D008862:Microsomes, Liver / Q000276:immunology; D012254:Ribavirin / Q000627:therapeutic use; D012793:Sialadenitis / Q000276:immunology / Q000821:virology; D013967:Thyroiditis, Autoimmune / Q000821:virology
D000998:Antiviral Agents; D001323:Autoantibodies; D016898:Interferon-alpha; D012254:Ribavirin